Clinical Features and Outcomes of Immunocompromised Children Hospitalized With Laboratory-Confirmed Influenza in the United States, 2011-2015
- PMID: 30358877
- DOI: 10.1093/jpids/piy101
Clinical Features and Outcomes of Immunocompromised Children Hospitalized With Laboratory-Confirmed Influenza in the United States, 2011-2015
Abstract
Background: Existing data on the clinical features and outcomes of immunocompromised children with influenza are limited.
Methods: Data from the 2011-2012 through 2014-2015 influenza seasons were collected as part of the Centers for Disease Control and Prevention (CDC) Influenza Hospitalization Surveillance Network (FluSurv-NET). We compared clinical features and outcomes between immunocompromised and nonimmunocompromised children (<18 years old) hospitalized with laboratory-confirmed community-acquired influenza. Immunocompromised children were defined as those for whom ≥1 of the following applies: human immunodeficiency virus/acquired immunodeficiency syndrome, cancer, stem cell or solid organ transplantation, nonsteroidal immunosuppressive therapy, immunoglobulin deficiency, complement deficiency, asplenia, and/or another rare condition. The primary outcomes were intensive care admission, duration of hospitalization, and in-hospital death.
Results: Among 5262 hospitalized children, 242 (4.6%) were immunocompromised; receipt of nonsteroidal immunosuppressive therapy (60%), cancer (39%), and solid organ transplantation (14%) were most common. Immunocompromised children were older than the nonimmunocompromised children (median, 8.8 vs 2.8 years, respectively; P < .001), more likely to have another comorbidity (58% vs 49%, respectively; P = .007), and more likely to have received an influenza vaccination (58% vs 39%, respectively; P < .001) and early antiviral treatment (35% vs 27%, respectively; P = .013). In multivariable analyses, immunocompromised children were less likely to receive intensive care (adjusted odds ratio [95% confidence interval], 0.31 [0.20-0.49]) and had a slightly longer duration of hospitalization (adjusted hazard ratio of hospital discharge [95% confidence interval], 0.89 [0.80-0.99]). Death was uncommon in both groups.
Conclusions: Immunocompromised children hospitalized with influenza received intensive care less frequently but had a longer hospitalization duration than nonimmunocompromised children. Vaccination and early antiviral use could be improved substantially. Data are needed to determine whether immunocompromised children are more commonly admitted with milder influenza severity than are nonimmunocompromised children.
Keywords: HIV/AIDS; cancer; immunosuppressed; outcomes; pediatric; transplant.
© The Author(s) 2018. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Similar articles
-
Outcomes of Immunocompromised Adults Hospitalized With Laboratory-confirmed Influenza in the United States, 2011-2015.Clin Infect Dis. 2020 May 6;70(10):2121-2130. doi: 10.1093/cid/ciz638. Clin Infect Dis. 2020. PMID: 31298691 Free PMC article.
-
Morbimortality of pandemic influenza A H1N1 infection in kidney transplant recipients requiring hospitalization: a comparative analysis with nonimmunocompromised patients.Transplantation. 2012 Jan 15;93(1):69-72. doi: 10.1097/TP.0b013e31823aa528. Transplantation. 2012. PMID: 22203390
-
Does Influenza Vaccination Modify Influenza Severity? Data on Older Adults Hospitalized With Influenza During the 2012-2013 Season in the United States.J Infect Dis. 2015 Oct 15;212(8):1200-8. doi: 10.1093/infdis/jiv200. Epub 2015 Mar 27. J Infect Dis. 2015. PMID: 25821227 Free PMC article.
-
Influenza vaccination in immunocompromised patients: efficacy and safety.Immunotherapy. 2014;6(2):131-9. doi: 10.2217/imt.13.171. Immunotherapy. 2014. PMID: 24491087 Review.
-
Pediatric influenza.Pediatr Nurs. 2009 Nov-Dec;35(6):335-45. Pediatr Nurs. 2009. PMID: 20166462 Review.
Cited by
-
Contribution of immunoglobulin products in influencing seasonal influenza infection and severity in antibody immune deficiency patients receiving immunoglobulin replacement therapy.Front Immunol. 2024 Oct 22;15:1452106. doi: 10.3389/fimmu.2024.1452106. eCollection 2024. Front Immunol. 2024. PMID: 39502688 Free PMC article. Review.
-
Association of Chronic Medical Conditions With Severe Outcomes Among Nonpregnant Adults 18-49 Years Old Hospitalized With Influenza, FluSurv-NET, 2011-2019.Open Forum Infect Dis. 2023 Nov 29;10(12):ofad599. doi: 10.1093/ofid/ofad599. eCollection 2023 Dec. Open Forum Infect Dis. 2023. PMID: 38130595 Free PMC article.
-
Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response.Front Immunol. 2022 May 19;13:878943. doi: 10.3389/fimmu.2022.878943. eCollection 2022. Front Immunol. 2022. PMID: 35663997 Free PMC article. Review.
-
Hospitalizations of Children Aged 5-11 Years with Laboratory-Confirmed COVID-19 - COVID-NET, 14 States, March 2020-February 2022.MMWR Morb Mortal Wkly Rep. 2022 Apr 22;71(16):574-581. doi: 10.15585/mmwr.mm7116e1. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35446827 Free PMC article.
-
Risk Factors for Severe COVID-19 in Children.Pediatrics. 2022 Jan 1;149(1):e2021053418. doi: 10.1542/peds.2021-053418. Epub 2021 Dec 22. Pediatrics. 2022. PMID: 34935038 Free PMC article.

